Cover Image
市場調查報告書

美國的藥物遞輸產品市場預測

Drug Delivery Products (US Market & Forecast)

出版商 Freedonia Group 商品編碼 230864
出版日期 內容資訊 英文 373 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
美國的藥物遞輸產品市場預測 Drug Delivery Products (US Market & Forecast)
出版日期: 2015年12月31日 內容資訊: 英文 373 Pages
簡介

美國的藥物遞輸產品需求,今後預計以年率6.1%擴大,2019年成長到2,510億美元。

提供著 本報告提供美國的藥物遞輸市場現況與展望調查分析、各賦形劑/產品類型/應用領域的市場實際成果(2004年、2009年、2014年)及預測(2019年、2024年)資料、市場影響因素、產業結構、市場佔有率、27家主要企業簡介等彙整結果,為您概述為以下內容。

簡介

第1章 摘要整理

第2章 市場環境

  • 概要
  • 經濟要素
  • 人口統計模式
  • 醫療保健趨勢
  • 製藥市場概要

第3章 藥物遞輸賦形劑

  • 概要
  • 聚合物
    • 聚乙二醇
    • 丙烯聚合物
    • 氧化聚乙烯
    • 聚乙烯醇
    • 其他的合成聚合物
  • 纖維素賦形劑
    • 乙基纖維素
    • 羥丙基甲基纖維素
    • 其他的纖維素賦形劑
  • 礦物質
    • 礦物質烴
    • 其他的礦物質
  • 其他的賦形劑
    • 殺菌水、純淨水
    • 澱粉複合物
    • 砂糖、多元醇
    • 天然口香糖
    • 其他的賦形劑

第4章 藥物遞輸產品概要

  • 概要
  • 產品類型
  • 過去的市場趨勢
  • 法規
  • 研究開發
  • 美國的貿易
  • 國際市場

第5章 口服藥物遞輸產品

  • 概要
  • 控釋製劑
  • 咀嚼錠
  • 奈米粒子製劑
  • (ODT)
  • 粘膜製劑

第6章 非口服藥物遞輸產品

  • 概要
  • 治療用單株抗體
  • 膠囊型非口服藥物遞輸產品
  • 注射產品
  • 非口服藥物遞輸設備

第7章 其他藥物遞輸產品

  • 概要
  • 吸入藥物遞輸產品
  • 置入式藥物遞輸產品
  • 經皮給藥產品

第8章 應用

  • 概要
  • 中樞神經系統藥
  • 呼吸系統藥
  • 荷爾蒙、相關醫藥品
  • 腸胃藥
  • 心臟血管藥
  • 抗感染藥
  • 營養劑
  • 泌尿生殖系統藥
  • 其他的醫藥品

第9章 產業結構

  • 概要
  • 市場佔有率
  • 競爭策略
  • M&A
  • 授權、相關協定
  • 行銷、流通
  • 製造

企業簡介

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 3354

US demand to reach $251 billion in 2019

US demand for drug delivery products is forecast to grow 6.1 percent annually to $251 billion in 2019. Specialized dosage formulations that improve therapies for autoimmune, cancer, cardiovascular, neurological, viral, and other debilitating disorders will lead gains. Included in this group are human and humanized monoclonal antibodies, polymer-encapsulated medicines, and brachytherapy seeds. Among drug delivery devices, pen injectors and retractable prefillable syringes will record the fastest revenue growth based on safety, infection prevention, and ease-of-use advantages.

Demand for oral drug delivery products will benefit from bioavailability and reduced dosing advantages, while controlled-release formulations will continue to dominate revenues. On the downside, patent expirations and generic competition will soften overall growth potential for this product segment.

Prefillable syringes to lead strong gains in parenteral drug delivery

US demand for parenteral drug delivery products is projected to post double-digit gains through 2019. Advances in monoclonal antibodies and polymer-encapsulated medicines will underlie growth. The use of new and existing therapies based on human and humanized monoclonal antibodies will improve the effectiveness of remedies against various forms of cancer and other long-term disorders, such as allergy-linked asthma, Crohn's disease, rheumatoid and psoriatic arthritis, and wet age-related macular degeneration. Enhanced bioavailability and reduced toxicity advantages will boost applications for polymer-enhanced medicines in the treatment of conditions such as cancer complications, hepatitis B and C, and multiple sclerosis.

Among parenteral delivery devices, prefillable syringes will account for the largest and fastest expanding demand over the long term. Improvements in safety features such as automatic needle retraction, along with overall infection prevention and response time advantages, will benefit growth. Prefillable syringes will also broaden self-use applications based on advances in pen injectors and related apparatus.

Mixed outlook for inhalers

Demand for other drug delivery products is expected to surpass $34 billion in 2019. Dry powder and metered dose inhalers will account for more than three-fourths of revenues, reflecting upward trends in prevalence of asthma and chronic obstructive pulmonary disease (COPD). On the downside, growth prospects for inhalers will weaken gradually as patent expirations make several widely used respiratory therapies -- such as ADVAIR, SPIRIVA and SYMBICORT -- available to low cost generic competition.

Limited indications and competition from alternative therapies will hold down demand for transdermal drug delivery products. Within this product group, overactive bladder and estrogen replacement therapies will post the fastest revenue growth. Contraceptive inserts will draw the largest and fastest expanding revenues among implantable drug delivery products based on convenience and effectiveness advantages in birth control applications. Brachytherapy implants will also fare well in the marketplace, spurred by increasing use in cervical, prostate, breast, and skin cancer treatment. Im-plantable drug pumps will see moderate growth in demand as improvements in device safety broadens applications in the delivery of pain control and ophthalmic medication. Recent introductions and a rise in heart conditions will foster growth in the market for drug-eluting stents.

Study coverage

Drug Delivery Products presents historical demand data (2004, 2009 and 2014) plus forecasts (2019 and 2024) by product and application. The study also assesses key market environment factors, examines the industry structure, analyzes company market share and profiles 30 US industry competitors.

This study can help you:

  • Determine your market & sales potential
  • Learn more about industry competitors
  • Assess new products & technologies
  • Identify firms to merge with or acquire
  • Complement your research & planning
  • Gather data for presentations
  • Confirm your own internal data
  • Make better business decisions

Table of Contents

INTRODUCTION

I. EXECUTIVE SUMMARY

II. MARKET ENVIRONMENT

  • General
  • Economic Factors
  • Demographic Patterns
  • Healthcare Trends
    • Health Insurance Reforms
    • Medical Conditions
      • Acute Conditions
      • Chronic Conditions
    • National Health Expenditures
      • Spending Categories
      • Funding Sources
    • Medical Providers
      • Hospitals
      • Outpatient Facilities
      • Physicians
      • Skilled Nursing Homes
    • Patient Activity
      • Hospital Activity
      • Outpatient Activity
      • Surgical Procedures
    • Pharmaceutical Industry Overview
    • Regulation
    • Research & Development
    • Product Demand
      • Therapeutic Groups
      • Dosage Formulations
      • Regulatory Classes
      • Commercial Status

III. DRUG DELIVERY PRODUCT OVERVIEW

  • General
  • Types of Drug Delivery Products
  • Historical Market Trends
  • US Trade
  • International Markets

IV. ORAL DRUG DELIVERY PRODUCTS

  • General
  • Controlled-Release Formulations
    • Film-Coated Formulations
    • Diffusion Formulations
    • Reservoir Formulations
  • Chewable Tablets
  • Orally Disintegrating Tablets
  • Nanoparticulate Formulations
  • Transmucosal Formulations

V. PARENTERAL DRUG DELIVERY PRODUCTS

  • General
  • Therapeutic Monoclonal Antibodies
    • Technology
    • Products
      • HUMIRA (adalimumab)
      • REMICADE (infliximab)
      • RITUXAN (rituximab)
      • AVASTIN (bevacizumab)
      • HERCEPTIN (trastuzumab)
      • LUCENTIS (ranibizumab)
      • STELARA (ustekinumab)
      • XOLAIR (omalizumab)
      • TYSABRI (natalizumab)
      • Other Monoclonal Antibodies
      • New Products
      • Developmental Products
  • Encapsulated Parenteral Formulations
    • Polymer-Protected Formulations
      • PEG-Based Parenteral Therapies
      • Other Polymer-Protected Parenteral Therapies
      • Developmental Activities
    • Liposomes
      • Technology
      • Marketed Products
      • Developmental Activities
    • Infusion Products
      • IV Administration Sets
      • Premixed IV Solutions
      • Infusion Pumps
      • Other Infusion Products
        • Enteral Feeding Supplies
        • IV Accessories
  • Parenteral Devices
    • Prefillable Syringes
      • Injectors
      • Cartridge Systems
    • Hypodermic Syringes
    • IV Catheters
    • Other Parenteral Devices

VI. OTHER DRUG DELIVERY PRODUCTS

  • General
  • Inhalation Drug Delivery Products
    • Dry Powder Formulations
    • Metered Dose Formulations
  • Transdermal Drug Delivery Products
    • Transdermal Technologies
    • Central Nervous System Agents
    • Hormones & Related Agents
    • Cardiovascular Agents
    • Other Transdermal Patches
  • Implantable Drug Delivery Products
    • Drug Inserts
    • Drug-Eluting Stents
    • Other Implantable Drug Delivery Products
      • Brachytherapy Products
      • Implantable Drug Pumps

VII. APPLICATIONS

  • General
  • Central Nervous System Agents
    • Controlled-Release Formulations
    • Other Oral Drug Delivery Products
    • Transdermal Formulations
    • Monoclonal Antibodies & Polymer Encapsulated Therapies
    • Liposomes
    • Other Drug Delivery Products
  • Hormones & Related Agents
    • Anticancer Monoclonal Antibodies
    • Encapsulated Polymers
    • Liposomes
    • Insulin Pen Injectors
    • Controlled-Release & Other Oral Drug Delivery Products
    • Transdermal Hormones & Related Agents
    • Other Drug Delivery Products
  • Respiratory Agents
    • Dry Powder Inhalers
    • Metered Dose Inhalers
    • Monoclonal Antibodies
  • Anti-Infective Agents
  • Cardiovascular Agents
    • Controlled-Release Formulations
    • Monoclonal Antibodies
    • Drug-Eluting Stents
    • Transdermal Patches
  • Gastrointestinal Agents
  • Nutritional Agents
  • Other Pharmaceuticals

VIII. INDUSTRY STRUCTURE

  • General
  • Market Share
    • Dosage Formulations
    • Devices
  • Competitive Strategies
  • Mergers & Acquisitions
  • Licensing & Related Agreements
  • Marketing & Distribution
  • Manufacturing

Company Profiles

  • Abbott Laboratories
  • AbbVie Incorporated
  • Actavis, see Allergan
  • Adare Pharmaceuticals Incorporated
  • Allergan plc
  • Amgen Incorporated
  • Animas, see Johnson & Johnson
  • Aptalis Pharma, see Allergan
  • Aptalis Pharmaceutical Technologies, see Adare
  • Pharmaceuticals
  • AptarGroup Incorporated
  • AstraZeneca plc
  • Baxter International Incorporated
  • Becton, Dickinson, and Company
  • Boehringer Ingelheim GmbH
  • Braun (B.) Melsungen AG
  • Bristol-Myers Squibb Company
  • CareFusion, see Becton, Dickinson
  • Evonik Industries AG
  • Forest Laboratories, see Allergan
  • Genentech, see Roche Holding
  • Genzyme, see Sanofi
  • Gerresheimer AG
  • Gilead Sciences Incorporated
  • GlaxoSmithKline plc
  • Hospira, see Pfizer
  • ImClone Systems, see Lilly (Eli)
  • Janssen Pharmaceuticals, see Johnson & Johnson
  • Johnson & Johnson
  • Lilly (Eli) and Company
  • MedImmune, see AstraZeneca
  • Merck & Company Incorporated
  • Nitto Denko Corporation
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Incorporated
  • Regeneron Pharmaceuticals, see Sanofi
  • Roche Holding Limited
  • Sanofi
  • Teva Pharmaceutical Industries Limited
  • 3M Company
  • Unilife Corporation
  • Vetter Pharma International GmbH
  • West Pharmaceutical Services Incorporated
  • Additional Companies in the Drug Delivery Product Market

LIST OF TABLES

SECTION I -- EXECUTIVE SUMMARY

  • Summary Table

SECTION II -- MARKET ENVIRONMENT

  • Macroeconomic Indicators
  • Resident Population by Age Group
  • Health Insurance Coverage of the US Population, 2004-2014
  • Acute Conditions by Type
  • Chronic Conditions by Type
  • National Health Expenditures by Spending Category
  • National Health Expenditures by Funding Source
  • Medical Providers by Type
  • Patient Activity by Type
  • Pharmaceutical Demand by Therapeutic Class
  • Pharmaceutical Demand by Dosage Formulation
  • Pharmaceutical Demand by Regulatory Classification
  • Pharmaceutical Demand by Patent Status

SECTION III -- DRUG DELIVERY PRODUCT OVERVIEW

  • Drug Delivery Product Demand by Type
  • Drug Delivery Product Demand Patterns, 2004-2014
  • US Trade in Drug Delivery Products
  • World Drug Delivery Product Demand by Region

SECTION IV -- ORAL DRUG DELIVERY PRODUCTS

  • Oral Drug Delivery Product Demand by Type
  • Controlled-Release Oral Drug Delivery Product Demand
  • Film-Coated Oral Drug Delivery Product Demand
  • Diffusion Oral Drug Delivery Product Demand
  • Reservoir Oral Drug Delivery Product Demand
  • Chewable Tablet Product Demand by Therapeutic Class
  • Orally Disintegrating Tablet Demand by Therapeutic Class
  • Oral Nanoparticulate Drug Delivery Product Demand by
  • Therapeutic Class
  • Transmucosal Drug Delivery Product Demand by
  • Therapeutic Class

SECTION V -- PARENTERAL DRUG DELIVERY PRODUCTS

  • Parenteral Drug Delivery Product Demand by Type
  • Therapeutic Monoclonal Antibody Demand by Therapeutic Class
  • Encapsulated Parenteral Product Demand by Type & Therapeutic Class
  • Infusion Product Demand by Type
  • Parenteral Device Demand by Type

SECTION VI -- OTHER DRUG DELIVERY PRODUCTS

  • Other Drug Delivery Product Demand by Type
  • Inhalation Drug Delivery Product Demand by Type
  • Dry Powder Inhaler Demand
  • Metered Dose Inhaler Demand
  • Transdermal Drug Delivery Product Demand by
  • Therapeutic Class
  • Implantable Drug Delivery Product Demand by Type
  • Drug Insert Demand by Therapeutic Class
  • Drug-Eluting Stent Demand
  • Other Implantable Drug Delivery Product Demand by Type

SECTION VII -- APPLICATIONS

  • Drug Delivery Product Demand by Therapeutic Class
  • Central Nervous System Drug Delivery Product Demand by Type
  • Hormone & Related Drug Delivery Product Demand by Type
  • Respiratory Drug Delivery Product Demand by Type
  • Anti-Infective Drug Delivery Product Demand by Type
  • Cardiovascular Drug Delivery Product Demand by Type
  • Gastrointestinal Drug Delivery Product Demand by Type
  • Nutritional Preparation Delivery Product Demand by Type
  • Other Application Drug Delivery Product Demand by Type

SECTION VIII -- INDUSTRY STRUCTURE

  • US Drug Delivery Product Sales by Company, 2014
  • Selected Acquisitions & Divestitures
  • Selected Cooperative Agreements

LIST OF CHARTS

SECTION III -- DRUG DELIVERY PRODUCT OVERVIEW

  • Drug Delivery Product Demand by Type, 2014

SECTION V -- PARENTERAL DRUG DELIVERY PRODUCTS

  • Parenteral Drug Delivery Product Demand by Type, 2014

SECTION VII -- APPLICATIONS

  • Drug Delivery Product Demand by Therapeutic Class, 2014

SECTION VIII -- INDUSTRY STRUCTURE

  • Drug Delivery Formulations, US Market Share, 2014
  • Drug Delivery Devices, US Market Share, 2014
Back to Top